Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.

You may also be interested in...



Utah Attorney General Sues Lilly For Medicaid Funds Spent On Zyprexa

State also has assumed cost of caring for recipients who consumed prescriptions that were “actively harmful,” AG claims.

Utah Attorney General Sues Lilly For Medicaid Funds Spent On Zyprexa

State also has assumed cost of caring for recipients who consumed prescriptions that were “actively harmful,” AG claims.

Grassley Seeking Zyprexa Lawsuit Documents

Senate Finance Committee ranking member requests all documents and materials relating to product liability litigation involving Lilly’s antipsychotic by April 25.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel